Диагностиканың ЖӘне емдеудің клиникалық хаттамасы 1 типті қант диабеті
Мүдделер қақтығысының жоқтығын көрсету
жүктеу/скачать 0.94 Mb. Pdf көрінісі
|
- Бұл бет үшін навигация:
- 7.4 Хаттаманы қайта қарау шарттарын көрсету
| 7.2 Мүдделер қақтығысының жоқтығын көрсету: жоқ.
7.3 Рецензенттер: Еспенбетова Майра Жақсыманқызы – медицина ғылымдарының докторы, профессор, Семей мемлекеттік медицина академиясының жалпы дәрігерлік практика бойынша интернатура кафедрасының меңгерушісі. 7.4 Хаттаманы қайта қарау шарттарын көрсету: жарияланғаннан кейін және қолданысқа енгізілген күнінен бастап 5 жыл өткен соң немесе дәлелділік деңгейі бар жаңа әдістер болған кезде хаттама қайта қаралады. 7.5 Пайдаланылған әдебиеттер тізімі: 1) American Diabetes Association. Standards of medical care in diabetes - 2017. Diabetes Care, 2017, Volume 40 (Supplement 1). 2) World Health Organization. Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complicatios: Report of a WHO consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Organization, 1999 (WHO/NCD/NCS/99.2). 3) Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова, 8-й выпуск. Москва, 2017. 4) World Health Organization. Use of Glycated Haemoglobin (HbAlc) in the Diagnosis of Diabetes Mellitus. Abbreviated Report of a WHO Consultation. World Health Organization, 2011 (WHO/NMH/CHP/CPM/11.1). 5) Базарбекова Р.Б., Нурбекова А.А., Даньярова Л.Б., Досанова А.К. Консенсус по диагностике и лечению сахарного диабета. Алматы, 2016. 6) Deutsche Diabetes Gesellschaft und Deutsche Vereinte Gesellschaftfür Klinische Chemie und Labormedizin, 2016. 7) Pickup J., Phil B. Insulin Pump Therapy for Type 1 Diabetes Mellitus, N Engl Med 2012; 366:1616-24. 13 8) Rossetti P, Porcellati F, Fanelli CG, Perriello G, Torlone E, BolliGB. Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. Arch Physiol Biochem. 2008 Feb;114(1):3-10. 9) White NH, Chase HP, Arslanian S, Tamborlane WV; 4030 Study Group. Comparison of glycemic variability associated with insulin glargine and intermediate- acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes.Diabetes Care. 2009 Mar;32(3):387-93. doi: 10.2337/dc08-0800. 10) L. L. Ilag, M. A. Deeg, T. Costigan, P. Hollander, T. C. Blevins, S. V. Edelman, et al. Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus®insulin glargine in patients with type 1 or type 2 diabetes mellitus. Diabetes Obesity and Metabolism, January 8, 2016. 11) Gilor C, Ridge TK, Attermeier KJ, Graves TK. Pharmacodynamics of insulin detemir and insulin glargine assessed by an isoglycemic clamp method in healthy cats.J Vet Intern Med. 2010 Jul-Aug; 24(4):870-4. 12) Fogelfeld L, Dharmalingam M, Robling K, Jones C, Swanson D, Jacober S. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes.Diabet Med. 2010 Feb;27(2):181-8. 13) Reynolds LR. Comparing insulins detemir and glargine in type 2 diabetes: more similarities than differences. Commentary. Postgrad Med. 2010 Jan;122(1):201-3. 14) Zinman B, Philis-Tsimikas A, Cariou B, et al; on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators. Diabetes Care. 2012;35(12):2464-2471. 15) Heller S, Buse J, Fisher M, et al; on behalf of the BEGIN Basal-Bolus Type 1 Trial Investigators. Lancet. 2012;379(9825):1489-1497. 16) Gough SCL, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Diabetes Care. 2013;36(9):2536-2542. 17) Meneghini L, Atkin SL, Gough SCL, et al; on behalf of the NN1250-3668 (BEGIN FLEX) Trial Investigators. Diabetes Care. 2013;36(4):858-864. 18) A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus (BEGIN™) ClinicalTrials.gov Identifier: NCT01513473. 19) Dailey G, Lavernia F. A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine.Diabetes ObesMetab. 2015;17:1107-1. 20) Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, Riddle MC. New Insulin Glargine 300 Units/mL VersusGlargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). DiabetesCare. 2015 Dec;38(12):2217-25. 21) Guideline on Similar Biological Medicinal Products Containing Biotechnology- derived Proteins as Drug Substance – Non Clinical and Clinical Issues. European Medicines Agency.18 December 2014 EMEA/CHMP/BMWP/42832/2005 Rev1 Committee for Medicinal Products for Human Use (CHMP). 22) “Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues”. European 14 Medicines Agency.26 February 2015 EMEA/CHMP/BMWP/32775/2005_Rev. 1 Committee for Medicinal products for Human Use (CHMP). 23) Z. Hochberg. Practical algorithms in pediatric endocrinology - Haifa, 2017, стр. 106. жүктеу/скачать 0.94 Mb. Достарыңызбен бөлісу:
|